Clinical Trial Update: Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial indicates that chronic reduction of fasting glycaemia with insulin glargine improves first- and second-phase insulin secretion in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Ruhr University of Bochum | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED